|
|
|
| Clinical effect of Anlotinib anti-angiogenesis combined with radiotherapy and chemotherapy in the treatment of middle-advanced non-small cell lung cancer |
| LI Zhen-bin1 CHEN Xuan1▲ YI Wu-qiang2 TANG Xiao-mei1 ZHANG Li1 YI Xiang-jun |
1.Department of Oncology, Jiangxi Chest Hospital, Jiangxi Province, Nanchang 330010, China;
2.Department of Internal Medicine, Xinjian District Traditional Chinese Medicine Hospital, Jiangxi Province, Nanchang 330010, China |
|
|
|
|
Abstract Objective To investigate the clinical effect of antiangiogenesis with Anlotinib combined with radiotherapy and chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).Methods A total of 80 patients with advanced NSCLC admitted to Jiangxi Chest Hospital from January 2019 to May 2020 were selected as the research subjects, and they were divided into group A, B, C and D according to random number table method, with 20 patients in each group.Group A was treated with Anlotinib anti-angiogenesis+chemoradiotherapy, group B was treated with Anlotinib anti-angiogenesis+radiotherapy, group C was treated with Anlotinib anti-angiogenesis+chemotherapy, and group D was treated with chemotherapy alone.The remission rate, the incidence of adverse reactions of the four groups were compared.Results The remission rate of group A was higher than those of group B, C and D, and the differences were statistically significant (P＜0.05).There was no significant difference in the remission rate among B, C and D groups (P＞0.05).There were no significant differences in the incidence of fever, fatigue, nausea and vomiting, bone marrow suppression and radiation pneumonia among the four groups (P＞0.05).Conclusion Anlotinib anti-angiogenesis combined with radiotherapy and chemotherapy can improve the local tumor control effect of patients with middle-advanced NSCLC, and it has high safety and is worthy of promotion.
|
|
|
|
|
|
| [1] |
张士放，文艳梅，陈红，等.靶向抗血管生成治疗非小细胞肺癌的研究进展[J].山东医药，2017，57（14）：107-110.
|
| [2] |
王中泰，吴芳，颜彬桔，等.进展期非小细胞肺癌抗血管生成治疗进展[J].中国肿瘤临床，2018，45（19）：973-979.
|
| [3] |
陆婉玲，李小龙，党亚正，等.DC-CIK 免疫疗法联合放化疗治疗中晚期非小细胞肺癌疗效观察[J].疑难病杂志，2020，19（8）：804-807，827.
|
| [4] |
俞昌赫.多西他赛联合阿帕替尼二线治疗进展期非小细胞肺癌的临床研究[J].中国临床药理学杂志，2019，35（22）：2812-2814，2818.
|
| [5] |
马胜林，陈雪琴.晚期肺癌抗血管生成治疗的临床应用进展[J].浙江医学，2019，41（23）：2453-2457，2476.
|
| [6] |
高亭，何小鹏，李敏，等.安罗替尼一线治疗晚期非小细胞肺癌的临床疗效观察[J].浙江医学，2019，41（23）：2543-2545.
|
| [7] |
赵秧，陈倩，康马飞，等.安罗替尼治疗晚期胰腺癌疗效观察[J].中国现代医生，2020，58（1）：121-123，126.
|
| [8] |
孙燕，周际昌.临床肿瘤内科手册（第三版）[M].北京：人民卫生出版社，2008：462.
|
| [9] |
杨学宁，吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学，2004，4（2）：85-90.
|
| [10] |
明伟石，升晔王，振武徐，等.阿帕替尼治疗晚期非小细胞肺癌的疗效[J].临床与病理杂志，2017，37（9）：1880-1886.
|
| [11] |
许涛，景红霞，李林均，等.培美曲塞/卡铂同步放化疗联合DC-CIK 对局部晚期非鳞癌非小细胞肺癌的疗效[J].广东医学，2016，37（7）：1070-1074.
|
| [12] |
林永娟，冯（契）.抗血管生成药物治疗晚期非小细胞肺癌的研究进展[J].医学综述，2017，23（15）：2983-2987.
|
| [13] |
王艳茹.重组人血管内皮抑制素注射液抗血管生成联合化疗在非小细胞肺癌患者中的应用[J].中国当代医药，2020，27（31）：100-102.
|
| [14] |
王昌平，黄珣，杨丽，等.DP 方案联合肿瘤抗血管生成药物在非小细胞肺癌治疗中的效果研究[J].实用临床医药杂志，2017，21（17）：58-60.
|
| [15] |
刘洁，王秀问.培美曲塞/多西他赛二线化疗晚期非小细胞肺癌预后因素分析[J].中国医师进修杂志，2018，41（8）：717-723.
|
| [16] |
王亚磊，王燕.抗血管生成药物治疗晚期非鳞状非小细胞肺癌的研究进展[J].癌症进展，2018，16（10）：16-21.
|
| [17] |
魏照光，成彦霖，王长青，等.盐酸安罗替尼胶囊治疗晚期非小细胞肺癌的临床效果[J].中国当代医药，2020，27（34）：111-113.
|
| [18] |
戴秀梅，张有为，韩亮，等.安罗替尼治疗晚期非小细胞肺癌的临床效果[J].中国医药导报，2019，16（32）：95-98.
|
| [19] |
徐建平，赵洁婷，叶伟，等.HGF，c-MET 及VEGF 在非小细胞肺癌中的表达和意义[J].实用癌症杂志，2017，32（4）：528-530，535.
|
| [20] |
陈锡山，邹文，杜祯，等.同步放化疗与新辅助化疗联合手术加辅助放疗治疗Ⅱb 期宫颈癌的对比分析[J].现代肿瘤医学，2017，25（15）：2467-2471.
|
| [21] |
斯晓燕，王汉萍，张晓彤，等.安罗替尼治疗晚期非小细胞肺癌16 例临床分析[J].中华内科杂志，2018，57（11）：830-834.
|
|
|
|
